The Wilson Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Wilson Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Wilson Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Wilson Disease and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Wilson Disease by 14 companies/universities/institutes. The top development phase for Wilson Disease is discovery with nine drugs in that stage. The Wilson Disease pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Wilson Disease pipeline products market are: DepYmed, Vivet Therapeutics and Generation Bio.
The key targets in the Wilson Disease pipeline products market include Copper Transporting ATPase 2 (Copper Pump 2 or Wilson Disease Associated Protein or ATP7B or EC 7.2.2.8), Copper, and Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48).
The key mechanisms of action in the Wilson Disease pipeline product include Copper Transporting ATPase 2 (Copper Pump 2 or Wilson Disease Associated Protein or ATP7B or EC 7.2.2.8) Activator with five drugs in Phase III. The Wilson Disease pipeline products include two routes of administration with the top ROA being Oral and five key molecule types in the Wilson Disease pipeline products market including Gene Therapy, and Small Molecule.
Wilson Disease overview
Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech and swallowing, and muscle stiffness. Treatment includes chelators and vitamin E supplements.
For a complete picture of Wilson Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
